Table 2.
Quality of life measures in the ADVANCE trial.
| ADVANCE Quality of life measures | Placebo (n = 214) | Atogepant 10 mg (n = 214) | Atogepant 30 mg (n = 223) | Atogepant 60 mg (n = 222) | |
|---|---|---|---|---|---|
| AIM-D | Mean monthly score at baseline (SD) | 15.2 (8.3) | 15.5 (8.9) | 16.9 (8.0) | 15.9 (8.3) |
| Change from baseline at week 12 (SE) | −6.1 (0.5) | −7.3 (0.5) | −8.6 (0.5) | −9.4 (0.5) | |
| Difference vs placebo (95% CI) | N/A | −1.2 (−2.6 to 0.2) | −2.5 (−3.9 to −1.2) | −3.3 (−4.7 to −2.0) | |
| p value | 0.09 | < 0.001 | < 0.001 | ||
| AIM-D score on physical impairment domain | Mean monthly score at baseline (SD) | 11.2 (8.1) | 11.7 (8.5) | 13.0 (8.0) | 11.6 (7.9) |
| Change from baseline at week 12 (SE) | −4.0 (0.4) | −5.1 (0.4) | −6.0 (0.4) | −6.5 (0.4) | |
| Difference vs placebo (95% CI) | N/A | −1.1 (−2.3 to 0.1) | −2.0 (−3.2 to −0.8) | −2.5 (−3.7 to −1.3) | |
| p value | 0.90 | 0.002 | < 0.001 | ||
| MSQ-9 | Mean monthly score at baseline (SD) | 46.8 (19.7) | 44.9 (21.4) | 44.0 (19.6) | 46.8 (20.4) |
| Change from baseline at week 12 (SE) | 20.4 (1.6) | 30.3 (1.6) | 30.5 (1.6) | 31.2 (1.6) | |
| Difference vs placebo (95% CI) | N/A | 9.9 (5.4 to 14.4) | 10.1 (5.7 to 14.5) | 10.8 (6.4 to 15.2) | |
| p-value | < 0.001 | < 0.001 | < 0.001 |
AIM-D: Activity Impairment in Migraine-Diary; SD: Standard deviation; SE: Standard Error; CI: Confidence Interval; N/A: Not Applicable; MSQ: Migraine-Specific Quality of Life Questionnaire.